42,265 Shares in Tandem Diabetes Care, Inc. $TNDM Bought by Counterpoint Mutual Funds LLC

Counterpoint Mutual Funds LLC purchased a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 42,265 shares of the medical device company’s stock, valued at approximately $513,000.

Several other institutional investors have also recently bought and sold shares of the business. Amalgamated Bank lifted its stake in shares of Tandem Diabetes Care by 3.5% in the third quarter. Amalgamated Bank now owns 19,617 shares of the medical device company’s stock valued at $238,000 after buying an additional 657 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Tandem Diabetes Care by 8.8% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,101 shares of the medical device company’s stock valued at $319,000 after purchasing an additional 1,384 shares during the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in Tandem Diabetes Care by 10.1% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,299 shares of the medical device company’s stock valued at $285,000 after purchasing an additional 1,399 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in Tandem Diabetes Care by 8.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 20,954 shares of the medical device company’s stock worth $391,000 after purchasing an additional 1,719 shares in the last quarter. Finally, Diversified Trust Co raised its stake in shares of Tandem Diabetes Care by 12.2% in the third quarter. Diversified Trust Co now owns 18,339 shares of the medical device company’s stock worth $223,000 after purchasing an additional 1,991 shares during the last quarter.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM opened at $28.26 on Tuesday. The company has a market capitalization of $1.93 billion, a P/E ratio of -9.21 and a beta of 1.68. The company’s 50-day moving average is $21.04 and its 200 day moving average is $17.16. The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.02 and a current ratio of 2.55. Tandem Diabetes Care, Inc. has a fifty-two week low of $9.98 and a fifty-two week high of $35.12.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, February 19th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04. The business had revenue of $290.38 million for the quarter, compared to analyst estimates of $277.14 million. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The company’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.01 earnings per share. On average, equities research analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Key Headlines Impacting Tandem Diabetes Care

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Q4 execution — Company beat on revenue and posted better-than-expected EPS in the latest quarter, with management signaling solid operational execution that underpins today’s buying interest. Article Title
• Positive Sentiment: Analyst action — Truist reaffirmed a “hold” but raised its price target (from $24 to $27), a modest vote of confidence that likely supported upside after the earnings beat. Article Title
• Neutral Sentiment: Company filing — Tandem confirmed it intends to privately place $200M aggregate principal of convertible senior notes due 2032 to qualified institutional buyers; terms/convertibility details and timing are subject to market conditions. This is a factual disclosure that creates financing optionality but also potential dilution risk. Article Title
• Neutral Sentiment: Earnings-call takeaways — Management signaled a strategic shift (pay-as-you-go transition and other initiatives) that investors should monitor for margin and cash-flow implications; these are longer-term operational items rather than immediate catalysts. Article Title
• Negative Sentiment: Convertible-debt market reaction — Media coverage and traders reacted negatively to the $200M convertible offering announcement, citing dilution and financing concerns; several wires reported immediate selling pressure after the news. Article Title
• Negative Sentiment: Institutional selling & flows — Reports that the Brown Capital Management Small Company Fund sold its TNDM position likely amplified volatility and contributed to near-term selling pressure. Article Title
• Negative Sentiment: Mixed analyst/target moves — Other published price-target notes are below current trading levels (e.g., a $22 target reported by some outlets), reinforcing mixed expectations and adding to intraday selling dynamics. Article Title

Analyst Upgrades and Downgrades

TNDM has been the topic of several analyst reports. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $25.00 target price (up previously from $18.00) on shares of Tandem Diabetes Care in a research report on Friday, January 9th. Mizuho set a $22.00 price objective on Tandem Diabetes Care and gave the company a “neutral” rating in a research note on Friday. Canaccord Genuity Group set a $35.00 target price on shares of Tandem Diabetes Care and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tandem Diabetes Care in a report on Wednesday, January 21st. Finally, Stifel Nicolaus boosted their price target on shares of Tandem Diabetes Care from $20.00 to $22.00 and gave the stock a “hold” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $28.00.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.